Endothelial and Microvascular Function

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 3, 2003, Pages 225-238

  Strümper, Danja ^b   Durieux, Marcel ^a   Roekaerts, Paul ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC SYSTEM; ANTIGEN PRESENTATION; AUTOREGULATION; BLOOD CLOTTING; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CELL GROWTH; CHOLINERGIC SYSTEM; ENDOTHELIUM; FIBRINOLYSIS; GAP JUNCTION; HOMEOSTASIS; LIPOPROTEIN METABOLISM; MICROVASCULATURE; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0242525651     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/108925320300700302     Document Type: Review

References (112)

1. Cocks TM, Angus JA: Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature 305:627-630, 1983.
2. Angus JA, Cocks TM, Satoh K: The alpha adrenoceptors on endothelial cells. Fed Proc 45:2355-2359, 1986.
3. Vanhoutte PM, Miller VM: Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med 87:1S-5S, 1989.
4. Richard V, Tanner FC, Tschudi M, et al: Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol 259:H1433-H1439, 1990.
5. Bockman CS, Jeffries WB, Abel PW: Binding and functional characterization of alpha-2 adrenergic receptor subtypes on pig vascular endothelium. J Pharmacol Exp Ther 267:1126-1133, 1993.
6. Bockman CS, Gonzalez-Cabrera I, Abel PW: Alpha-2 adrenoceptor subtype causing nitric oxide-mediated vascular relaxation in rats. J Pharmacol Exp Ther 278:1235-1243, 1996.
7. Dawes M, Chowienczyk PJ, Ritter JM: Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation 95:2293-2297, 1997.
8. Ferro A, Queen LR, Priest RM, et al: Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J Pharmacol 126:1872-1880, 1999.
9. Gray DW, Marshall I: Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol 107:684-690, 1992.
10. Schwinn DA, Lomasney JW, Lorenz W, et al: Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. J Biol Chem 265:8183-8189, 1990.
11. Cotecchia S, Schwinn DA, Randall RR, et al: Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc Natl Acad Sci USA 85:7159-7163, 1988.
12. Perez DM, Piascik MT, Graham RM: Solution-phase library screening for the identification of rare clones: Isolation of an alpha 1D-adrenergic receptor cDNA. Mol Pharmacol 40:876-883, 1991.
13. Bylund DB, Eikenberg DC, Hieble JP, et al: International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136, 1994.
14. Ford AP, Williams TJ, Blue DR, et al: Alpha 1-adrenoceptor classification: Sharpening Occam's razor. Trends Pharmacol Sci 15:167-170, 1994.
15. Hein L, Kobilka BK: Adrenergic receptor signal transduction and regulation. Neuropharmacology 34:357-366, 1995.
16. Zhong H, Minneman KP: Alpha1-adrenoceptor subtypes. Eur J Pharmacol 375:261-276, 1999.
17. Garcia-Sainz JA, Vazquez-Prado J, del Carmen Medina L: Alpha 1-adrenoceptors: Function and phosphorylation. Eur J Pharmacol 389:1-12, 2000.
18. Yang M, Ruan J, Voller M, et al: Differential regulation of human alpha1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 359:439-446, 1999.
19. Flavahan NA, Cooke JP, Shepherd JT, et al: Human postjunctional alpha-1 and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. J Pharmacol Exp Ther 241:361-365, 1987.
20. Bylund DB, Blaxall HS, Iversen LJ, et al: Pharmacological characteristics of alpha 2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol 42:1-5, 1992.
21. Nahorski SR, Barnett DB, Cheung YD: Alpha-adrenoceptor-effector coupling: Affinity states or heterogeneity of the alpha 2-adrenoceptor? Clin Sci (Lond) 68:39s-42s, 1985.
22. Bylund DB, Ray-Prenger C, Murphy TJ: Alpha-2A and alpha-2B adrenergic receptor subtypes: Antagonist binding in tissues and cell lines containing only one subtype. J Pharmacol Exp Ther 245:600-607, 1988.
23. Starke K: Alpha-adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 88:199-236, 1981.
24. Alabaster VA, Keir RF, Peters CJ: Comparison of potency of alpha 2-adrenoceptor antagonists in vitro: Evidence for heterogeneity of alpha 2-adrenoceptors. Br J Pharmacol 88:607-614, 1986.
25. Cotecchia S, Kobilka BK, Daniel KW, et al: Multiple second messenger pathways of alpha-adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem 265:63-69, 1990.
26. i-family G- proteins: Studies with pertussis toxin-resistant G-protein mutants. Biochem J 321:721-728, 1997.
27. Surprenant A, Horstman DA, Akbarali H, et al: A point mutation of the alpha 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science 257:977-980, 1992.
28. Eason MG, Liggett SB: Subtype-selective desensitization of alpha 2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2. J Biol Chem 267:25473-25479, 1992.
29. Heck DA, Bylund DB: Differential down-regulation of alpha-2 adrenergic receptor subtypes. Life Sci 62:1467-1472, 1998.
30. Starke K: Presynaptic alpha-autoreceptors. Rev Physiol Biochem Pharmacol 107:73-146, 1987.
31. Langer SZ: 25 years since the discovery of presynaptic receptors: Present knowledge and future perspectives. Trends Pharmacol Sci 18:95-99, 1997.
32. Muller-Schweinitzer E: Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn Schmiedebergs Arch Pharmacol 327:299-303, 1984.
33. Guimaraes S, Nunes JP: The effectiveness of alpha 2-adrenoceptor activation increases from the distal to the proximal part of the veins of canine limbs. Br J Pharmacol 101:387-393, 1990.
34. Molenaar P, Malta E, Jones CR, et al: Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br J Pharmacol 95:225-233, 1988.
35. Rohrer DK, Chruscinski A, Schauble EH, et al: Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-adrenergic receptors. J Biol Chem 274:16701-16708, 1999.
36. Dixon RA, Kobilka BK, Strader DJ, et al: Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321:75-79, 1986.
37. Frielle T, Collins S, Daniel KW, et al: Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc Natl Acad Sci USA 84:7920-7924, 1987.
38. Emorine LJ, Marullo S, Briend-Sutren MM, et al: Molecular characterization of the human beta 3-adrenergic receptor. Science 245:1118-1121, 1989.
39. Brown AM: Regulation of heartbeat by G protein-coupled ion channels. Am J Physiol 259:H1621-1628, 1990.
40. i, by beta-adrenergic receptors in reconstituted phospholipid vesicles. J Biol Chem 259:9351-9354, 1984.
41. Chaudhry A, MacKenzie RG, Georgic LM, et al: Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal 6:457-465, 1994.
42. Luttrell LM, Ferguson SS, Daaka Y, et al: Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655-661, 1999.
43. Bunemann M, Lee KB, Pals-Rylaarsdam R, et al: Desensitization of G-protein-coupled receptors in the cardiovascular system. Annu Rev Physiol 61:169-192, 1999.
44. O'Donnell SR, Wanstall JC: Responses to the beta 2-selective agonist procaterol of vascular and atrial preparations with different functional beta-adrenoceptor populations. Br J Pharmacol 84:227-235, 1985.
45. Begonha R, Moura D, Guimaraes S: Vascular beta-adrenoceptor-mediated relaxation and the tone of the tissue in canine arteries. J Pharm Pharmacol 47:510-513, 1995.
46. Edvinsson L, Owman C: Pharmacological characterization of adrenergic alpha and beta receptors mediating the vasomotor responses of cerebral arteries in vitro. Circ Res 35:835-849, 1974.
47. Guimaraes S: Further study of the adrenoceptors of the saphenous vein of the dog: Influence of factors which interfere with the concentrations of agonists at the receptor level. Eur J Pharmacol 34:9-19, 1975.
48. Sparks HV Jr, Bardenheuer H: Regulation of adenosine formation by the heart. Circ Res 58:193-201, 1986.
49. Schwartz LM, Bukowski TR, Ploger JD, et al: Endothelial adenosine transporter characterization in perfused guinea pig hearts. Am J Physiol Heart Circ Physiol 279:H1502-1511, 2000.
50. Tucker AL, Linden J: Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27:62-67, 1993.
51. Linden J: Cloned adenosine A3 receptors: Pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci 15:298-306, 1994.
52. Fredholm BB, Abbracchio MP, Burnstock G, et al: Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156, 1994.
53. Olah ME, Stiles GL: Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 35:581-606, 1995.
54. Fredholm BB, Arslan G, Halldner L, et al: Structure and function of adenosine receptors and their genes. Naunyn Schmiedebergs Arch Pharmacol 362:364-374, 2000.
55. Freissmuth M, Schutz W, Linder ME: Interactions of the bovine brain A1-adenosine receptor with recombinant G protein alpha-subunits. Selectivity for rGi alpha-3. J Biol Chem 266:17778-17783, 1991.
56. Munshi R, Pang IH, Sternweis PC, et al: A1 adenosine receptors of bovine brain couple to guanine nucleotide-binding proteins Gi1, Gi2, and Go. J Biol Chem 266:22285-22289, 1991.
57. Abebe W, Mustafa SJ: A1 adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle. Am J Physiol 275:L990-L997, 1998.
58. Parsons M, Young L, Lee JE, et al: Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J 14:1423-1431, 2000.
59. Liang BT: Direct preconditioning of cardiac ventricular myocytes via adenosine A1 receptor and KATP channel. Am J Physiol 271:H1769-H1777, 1996.
60. 2+ currents in rat dissociated supraoptic neurones via A1 receptors. J Physiol 526(Pt 2):313-326, 2000.
61. 2+ channels in rat hippocampal nerve terminals by the adenosine A1 receptor. Eur J Pharmacol 340:301-310, 1997.
62. Marala RB, Mustafa SJ: Direct evidence for the coupling of A2-adenosine receptor to stimulatory guanine nucleotide-binding-protein in bovine brain striatum. J Pharmacol Exp Ther 266:294-300, 1993.
63. Stefanovic V, Vlahovic P, Savic V, et al: Adenosine stimulates 5′-nucleotidase activity in rat mesangial cells via A2 receptors. FEBS Lett 331:96-100, 1993.
64. MacEwan DJ, Kim GD, Milligan G: Agonist regulation of adenylate cyclase activity in neuroblastoma x glioma hybrid NG108-15 cells transfected to co-express adenylate cyclase type II and the beta 2-adrenoceptor. Evidence that adenylate cyclase is the limiting component for receptor-mediated stimulation of adenylate cyclase activity. Biochem J 318:1033-1039, 1996.
65. Li SN, Wong PT: The adenosine receptor agonist, APNEA, increases calcium influx into rat cortical synaptosomes through N-type channels associated with A2a receptors. Neurochem Res 25:457-459, 2000.
66. Palmer TM, Gettys TW, Stiles GL: Differential interaction with and regulation of multiple G-proteins by the rat A3 adenosine receptor. J Biol Chem 270:16895-16902, 1995.
67. Atkinson MR, Townsend-Nicholson A, Nicholl JK, et al: Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci Res 29:73-79, 1997.
68. Abbracchio MP, Brambilla R, Ceruti S, et al: G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol 48:1038-1045, 1995.
69. Zhao Z, Francis CE, Ravid K: An A3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells: Its role in attenuating adenosine-induced increase in cAMP. Microvasc Res 54:243-252, 1997.
70. Zhao Z, Makaritsis K, Francis CE, et al: A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice. Biochim Biophys Acta 1500:280-290, 2000.
71. McCormack DG, Clarke B, Barnes PJ: Characterization of adenosine receptors in human pulmonary arteries. Am J Physiol 256:H41-46, 1989.
72. Reviriego J, Alonso MJ, Ibanez C, et al: Action of adenosine and characterization of adenosine receptors in human placental vasculature. Gen Pharmacol 21:227-233, 1990.
73. Sabouni MH, Hussain T, Cushing DJ, et al: G proteins subserve relaxations mediated by adenosine receptors in human coronary artery. J Cardiovasc Pharmacol 18:696-702, 1991.
74. Kemp BK, Cocks TM: Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. Br J Pharmacol 126:1796-1800, 1999.
75. Habazettl H, Conzen PF, Vollmar B, et al: Dilation of coronary microvessels by adenosine induced hypotension in dogs. Int J Microcirc Clin Exp 11:51-65, 1992.
76. Habazettl H, Vollmar B, Christ M, et al: Heterogeneous microvascular coronary vasodilation by adenosine and nitroglycerin in dogs. J Appl Physiol 76:1951-1960, 1994.
77. DeFily DV, Patterson JL, Chilian WM: Endogenous adenosine modulates alpha 2- but not alpha 1-adrenergic constriction of coronary arterioles. Am J Physiol 268:H2487-2494, 1995.
78. Doyle MP, Linden J, Duling BR: Nucleoside-induced arteriolar constriction: A mast cell-dependent response. Am J Physiol 266:H2042-2050, 1994.
79. Shepherd RK, Linden J, Duling BR: Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res 78:627-634, 1996.
80. Feigl EO, Neat GW, Huang AH: Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol 22:375-370, 1990.
81. Koch LG, Britton SL, Metting PJ: Adenosine is not essential for exercise hyperaemia in the hindlimb of conscious dogs. J Physiol 429:63-76, 1990.
82. Bassenge E, Heusch G: Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 116:77-165, 1990.
83. Michel T, Feron O: Nitric oxide synthases: Which, where, how, and why? J Clin Invest 100:2146-2152, 1997.
84. Rapoport RM, Murad F: Endothelium-dependent and nitrovasodilator-induced relaxation of vascular smooth muscle: Role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res 9:281-296, 1983.
85. Mayer B, Pfeiffer S, Schrammel A, et al: A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 273:3264-3270, 1998.
86. Lincoln TM: Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther 41:479-502, 1989.
87. Lincoln TM, Cornwell TL: Intracellular cyclic GMP receptor proteins. FASEB J 7:328-338, 1993.
88. White KA, Marletta MA: Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 31:6627-6631, 1992.
89. Forstermann U, Pollock JS, Schmidt HH, et al: Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 88:1788-1792, 1991.
90. Chen XL, Rembold CM: Cyclic nucleotide-dependent regulation of Mn2+ influx, [Ca2+]i, and arterial smooth muscle relaxation. Am J Physiol 263:C468-473, 1992.
91. Hirata M, Kohse KP, Chang CH, et al: Mechanism of cyclic GMP inhibition of inositol phosphate formation in rat aorta segments and cultured bovine aortic smooth muscle cells. J Biol Chem 265:1268-1273, 1990.
92. Holzmann S: Endothelium-induced relaxation by acetylcholine associated with larger rises in cyclic GMP in coronary arterial strips. J Cyclic Nucleotide Res 8:409-419, 1982.
93. Light DB, Corbin JD, Stanton BA: Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 344:336-339, 1990.
94. Rapoport RM: Cyclic guanosine monophosphate inhibition of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ Res 58:407-410, 1986.
95. Rumbaut RE, McKay MK, Huxley VH: Capillary hydraulic conductivity is decreased by nitric oxide synthase inhibition. Am J Physiol 268:H1856-H1861, 1995.
96. Kubes P: Nitric oxide affects microvascular permeability in the intact and inflamed vasculature. Microcirculation 2:235-244, 1995.
97. Kubes P: Nitric oxide-induced microvascular permeability alterations: A regulatory role for cGMP. Am J Physiol 265:H1909-H1915, 1993.
98. Arnhold S, Antoine D, Blaser H, et al: Nitric oxide decreases microvascular permeability in bradykinin stimulated and nonstimulated conditions. J Cardiovasc Pharmacol 33:938-947, 1999.
99. Sagach VF, Kindybalyuk AM, Kovalenko TN: Functional hyperemia of skeletal muscle: Role of endothelium. Journal of Cardiovascular Pharmacology 20:S170-S175, 1992.
100. Johnston CI, Risvanis J: Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues. Am J Hypertens 10:306S-310S, 1997.
101. Griendling KK, Ushio-Fukai M, Lassegue B, et al: Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 29:366-373, 1997.
102. Harrison DG: Endothelial function and oxidant stress. Clin Cardiol 20:II-11-17, 1997.
103. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 99:2027-2033, 1999.
104. Nakashima M, Vanhoutte PM: Age-dependent decrease in endothelium-dependent hyperpolarizations to endothelin-3 in the rat mesenteric artery. J Cardiovasc Pharmacol 22:S352-354, 1993.
105. Nelson MT, Patlak JB, Worley JF, et al: Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3-C18, 1990.
106. Beny JL, Gribi F: Dye and electrical coupling of endothelial cells in situ. Tissue Cell 21:797-802, 1989.
107. Beny JL, Pacicca C: Bidirectional electrical communication between smooth muscle and endothelial cells in the pig coronary artery. Am J Physiol 266:H1465-1472, 1994.
108. Marchenko SM, Sage SO: Electrical properties of resting and acetylcholine-stimulated endothelium in intact rat aorta. J Physiol 462:735-751, 1993.
109. Campbell WB, Harder DR: Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84:484-488, 1999.
110. Randall MD, Kendall DA: Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335:205-209, 1997.
111. Niederhoffer N, Szabo B: Involvement of CB1 cannabinoid receptors in the EDHF-dependent vasorelaxation in rabbits. Br J Pharmacol 126:1383-1386, 1999.
112. Mombouli JV, Vanhoutte PM: Endothelium-derived hyperpolarizing factor(s): Updating the unknown. Trends Pharmacol Sci 18:252-256, 1997.